Safety and Immunogenicity of Seven COVID-19 Vaccines as a Third Dose (Booster) After Two Doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A Phase 2, Multicenter, Randomized, Controlled Trial

0
11
Safety and Immunogenicity of Seven COVID-19 Vaccines as a Third Dose (Booster) After Two Doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A Phase 2, Multicenter, Randomized, Controlled Trial


IgG anti-pics SARS-CoV-2, ELU/mL GMC

*

Data are GM (95% CI; number of samples available).

763 (630-924 ; n=91) 20 517 (17 718–23 757 ; n=93) 1835 (1514-2224 ; n=93) 1430 (1198-1707 ; n=103) 5517 (4647-6548 ; n=98) 3197 (2714–3767 ; n=94) 27 242 (24148-30 731; n=96) 4204 (3640–4856 ; n=98) 3721 (3200–4326 ; n=98) 17 079 (14 488–20 133 ; n=87) GMR

??

GMRs of study vaccines were calculated by comparing to their corresponding controls in group A, B or C, after adjusting for age group, site, baseline anti-peak IgG, interval between the first and second dose and the interval between the second and third dose; for the primary endpoint of anti-peak IgG, 99% CIs were presented to account for multiple comparisons; for secondary endpoints, 95% CIs were presented.

Ref 24·48 (19·5-30·79) 2·20 (1·75-2·77) 1,81 (1,45-2,27) 5,84 (4,65–7,33) Ref 8·11 (6·59–9.99) 1·31 (1.07–1.62) 1,25 (1,01–1,54) 5·63 (4·55–6·97) Pseudotypic virus neutralizing antibody (wild type), NT50 GMT

*

Data are GM (95% CI; number of samples available).
69,6 (57,2–84,6 ; n=91) 1621 (1314-1998 ; n=93) 202 (166-247 ; n=89) 147 (124-174 ; n=95) 563 (454-698 ; n=95) 205 (167-253 ; n=93) 1789 (1520-2107 ; n=95) 289 (244-342 ; n=91) 234 (200-272 ; n=87) 1441 (1188-1749 ; n=75) GMR

??

GMRs of study vaccines were calculated by comparing to their corresponding controls in group A, B or C, after adjusting for age group, site, baseline anti-peak IgG, interval between the first and second dose and the interval between the second and third dose; for the primary endpoint of anti-peak IgG, 99% CIs were presented to account for multiple comparisons; for secondary endpoints, 95% CIs were presented.
Ref 21·58 (16·93–27·51) 2·68 (2·10–3,43) 2,01 (1,57–2,55) 6,85 (5,37-8,73) Ref 8·35 (6·88–10·14) 1·38 (1·14–1.68) 1,22 (1,00-1,49) 7,84 (6,37-9,64) Pseudotypic (delta) virus neutralizing antibody, NT50 GMT

*

Data are GM (95% CI; number of samples available).
20,4 (16,4-25,5 ; n=91) 315 (254-391 ; n=93) 35,2 (28,4–43,7 ; n=89) 31·1 (25,6–37,7 ; n=95) 125 (99-159 ; n=90) 56,5 (43,6–73,3 ; n=92) 392 (320-479 ; n=95) 67,1 (55,4–81,2 ; n=94) 54,7 (45,1–66,4 ; n=92) 418 (330-530 ; n=78) GMR

??

GMRs of study vaccines were calculated by comparing to their corresponding controls in group A, B or C, after adjusting for age group, site, baseline anti-peak IgG, interval between the first and second dose and the interval between the second and third dose; for the primary endpoint of anti-peak IgG, 99% CIs were presented to account for multiple comparisons; for secondary endpoints, 95% CIs were presented.
Ref 14,43 (10,97-18,98) 1·65 (1,25–2·17) 1,50 (1,14–1,96) 5,33 (4,04–7,03) Ref 6·60 (5·10–8·53) 1·19 (0,92–1,54) 1,02 (0,79-1,32) 8·02 (6·12–10·50) Live virus neutralizing antibody, NT normalized80 GMT

*

Data are GM (95% CI; number of samples available).
174 (139–218 ; n=30) 4899 (3955–6069 ; n=38) 354 (215-584 ; n=21) 301 (212–427 ; n=25) 1053 (691-1605 ; n=23) 756 (568–1007 ; n=34) 4603 (3685–5749 ; n=36) 836 (580-1207 ; n=20) 555 (407-756 ; n=23) 3535 (2459–5080 ; n=19) GMR

??

GMRs of study vaccines were calculated by comparing to their corresponding controls in group A, B or C, after adjusting for age group, site, baseline anti-peak IgG, interval between the first and second dose and the interval between the second and third dose; for the primary endpoint of anti-peak IgG, 99% CIs were presented to account for multiple comparisons; for secondary endpoints, 95% CIs were presented.
Ref 25·61 (18·07–36·31) 2·04 (1,37-3,05) 1,81 (1,23-2,65) 5,97 (4,03-8,84) Ref 5·79 (4·25–7·90) 1,42 (0,98-2,06) 0,93 (0,65-1,33) 5,36 (3,67–7,83) Cellular response (wild type), cells forming spots by 10

6

  • Bar-On YM
  • Goldberg Y
  • Mandel M
  • et al.

Protection of the BNT162b2 vaccine booster against COVID-19 in Israel.

peripheral blood mononuclear cells DG

*

Data are GM (95% CI; number of samples available).
42,6 (30,9–58,8 ; n=49) 115,5 (81,7–163,3 ; n=50) 52,2 (36,3–75 ; n=47) 55,5 (40,4–76,3 ; n=53) 106·0 (80·1–140,4 ; n=53) 29,4 (21,0–41,2 ; n=50) 83,8 (65,4–107,2 ; n=49) 33,5 (24,7–45,4 ; n=51) 38·1 (26·1–55,5 ; n=51) 111,0 (71,8–171,6 ; n=43) GMR

??

GMRs of study vaccines were calculated by comparing them to their corresponding controls in group A, B or C, after adjusting for age group, site, baseline cell response versus wild type, the interval between the first and the second dose and the interval between the second and third dose; 95% CIs were presented.
Ref 3·15 (2·08-4·76) 1·39 (0·92-2·11) 1,40 (0,93-2,11) 2,74 (1,82–4,12) Ref 2,65 (1,78-3,95) 1,04 (0,69–1,55) 1·12 (0·75–1.66) 2,93 (1,93–4,44) Cell response (delta), cells forming spots by 10

6

  • Bar-On YM
  • Goldberg Y
  • Mandel M
  • et al.

Protection of the BNT162b2 vaccine booster against COVID-19 in Israel.

peripheral blood mononuclear cells DG

*

Data are GM (95% CI; number of samples available).
42,2 (30,5–58,3 ; n=49) 123,2 (93,0–163,3 ; n=50) 52,8 (36,9–75,6 ; n=47) 54,7 (41,5–72,0 ; n=53) 102,1 (74,4–140,2 ; n=53) 28,2 (19,9–39,9 ; n=50) 82,1 (65,7–102,7 ; n=49) 29,6 (20,9–42,0 ; n=51) 39,2 (27,2–56,6 ; n=51) 121,5 (78,9–187,0 ; n=43) GMR

??

GMRs of study vaccines were calculated by comparing them to their corresponding controls in group A, B or C, after adjusting for age group, site, baseline cell response versus wild type, the interval between the first and the second dose and the interval between the second and third dose; 95% CIs were presented.
Ref 3·23 (2·15–4.86) 1,40 (0,93-2,12) 1,39 (0,93-2,08) 2,67 (1,79–4,00) Ref 2·71 (1·78–4·13) 0,96 (0,63-1,47) 1,22 (0,80-1,85) 3·29 (2·12–5·11) Cellular response (beta), cells forming spots by 10

6

  • Bar-On YM
  • Goldberg Y
  • Mandel M
  • et al.

Protection of the BNT162b2 vaccine booster against COVID-19 in Israel.

peripheral blood mononuclear cells DG

*

Data are GM (95% CI; number of samples available).
47,6 (35,2–64,4 ; n=49) 120,5 (88,0–165,0 ; n=50) 52,6 (36,3–76,3 ; n=47) 56,8 (41,0–78,7 ; n=53) 99,9 (72,6–137,6 ; n=53) 27,6 (19,9–38,5 ; n=50) 85,2 (69,8–103,9 ; n=49) 31·1 (22,5–42,9 ; n=51) 40,3 (28,1–57,7 ; n=51) 118,6 (78,3–179,7 ; n=43) GMR

??

GMRs of study vaccines were calculated by comparing them to their corresponding controls in group A, B or C, after adjusting for age group, site, baseline cell response versus wild type, the interval between the first and the second dose and the interval between the second and third dose; 95% CIs were presented.
Ref 2,88 (1,89–4,38) 1,25 (0,82–1,90) 1,28 (0,85–1,94) 2·30 (1,52–3,48) Ref 2,86 (1,92–4,28) 1,05 (0,70–1,56) 1,27 (0,85–1.89) 3·36 (2·21–5·10)

LEAVE A REPLY

Please enter your comment!
Please enter your name here